A sponsor’s injectable lipid lowering drug was in a first-to-market race against two competitors when it launched an eight-protocol, phase III global program. Six protocols were evaluating the LDL-C lowering efficacy, safety, and tolerability of the drug, and two studies were investigating its ability to reduce major cardiovascular events.
A sponsor began a multi-protocol, one-year phase III study to evaluate the safety and tolerability of its drug in subjects with essential hypertension.
This seven-year outcomes study is critical to the success of a compound that is expected to build on the sponsor’s
leadership position in diabetes care.
The sponsor’s original goal for this six-year trial was to enroll 18,000 patients. However, like most long-term studies, it turned out to be a very difficult and costly trial to enroll. After three and a half years, patient enrollment rates were far below commitments, and 750 U.S. sites had randomized only 2,200 subjects.
Acurian reads the pulse of CV studies.
We create a rhythm that will keep your trials on time and on budget, using data you can trust. Plus, we have a track record of resuscitating trials losing ground to attrition.
From atrial fibrillation to hypertension and stroke, we put our hearts into every aspect of patient enrollment and retention for these critical indications.
Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical
and biotech companies representing over 4,500 research sites.